PCDVD¼Æ¦ì¬ì§Þ°Q½×°Ï
PCDVD¼Æ¦ì¬ì§Þ°Q½×°Ï   µù¥U ±`¨£°ÝÃD ¼Ð°O°Q½×°Ï¬°¤wŪ

¦^¨ì   PCDVD¼Æ¦ì¬ì§Þ°Q½×°Ï > ¨ä¥L¸s²Õ > ¤C¼L¤K¦Þ²§¨¥°ó
±b¤á
±K½X
 

  ¦^À³
 
¥DÃD¤u¨ã
GCVincent
*°±Åv¤¤*
 

¥[¤J¤é´Á: Nov 2018
¤å³¹: 1,088
­^¤å wiki google ½Ķ
³o¸Ì­±´£¨ìªº¼Æ¦r¤w¸g¶W¹L30»õ¾¯¡]¦³ªº¨S¼g¼Æ¶q¡AµLªk­pºâ¡^¡C
3¤ë½÷·ç»¡2021¦~©³²£¶q¥i¥H´£¨Ñ¨ì25»õ¾¯¡C
¨S¬Ý¨ì³¢¸³ªº¡A©Î³\¬O§Q¥Î¤W®ü´_¬Pªº¤@»õÃB«×¡H
¨ä¥L°ê®a­n¥LÅý¥X¨Ó¥i¯à«ÜÃø¡H¡I
¤Þ¥Î:
¹w°â­q³æ ½s¿è
½÷·ç¦b¨ä 11 ¤ë 9 ¤éªº·s»D½Z¤¤ªí¥Ü ¡A¨ì 2020 ¦~©³¥i¥H´£¨Ñ5000¸U¾¯¡A¨ì 2021¦~¦b¥þ²y½d³ò¤º´£¨Ñ¬ù 13»õ¾¯¡C[34] 2021 ¦~ 2 ¤ë¡ABioNTech «Å¥¬±N¼W¥[ 50% ¥H¤Wªº²£¶q¦Ü 2021 ¦~¥Í²£ 20»õ¾¯¡A[197] 3 ¤ë©³¦A¦¸´£°ª¨ì 2021 ¦~ªº25»õ¾¯¡C[49]

2020 ¦~ 7 ¤ë¡A¬Ì­]¶}µo­p¹ºOperation Warp Speed¦V½÷·ç¤½¥q¤U¹F¤F19.5 »õ¬ü¤¸ªº¹wÁÊ­q³æ¡A¥Î©ó¥Í²£ 1 »õ¾¯ COVID-19 ¬Ì­]¡A¦pªG¸Ó¬Ì­]³QÃÒ©ú¬O¦w¥þ¦³®Äªº¡A«h¦b¬ü°ê¨Ï¥Î¡C[23] [198] [199] [200]¨ì 2020 ¦~ 12 ¤ë¤¤¦¯¡A½÷·ç¤w¹F¦¨¨óij¦V ¼Ú·ù¨ÑÀ³ 3»õ¾¯¡A[201] ¦V¤é¥»¨ÑÀ³1.2»õ¾¯¡A[202] 4,000 ¸U¾¯¡] ¤§«e¬°1000¸U¾¯¡^2021) ¨ì­^°ê¡A[79] 2000 ¸U¾¯¨ì¥[®³¤j¡A[203]¦V·s¥[©Y±µºØ¤F¼Æ¶q¤£¸Ôªº¬Ì­]¡A[204] ¦V¾¥¦è­ô±µºØ¤F 3440¸U¾¯¡C[205]´_¬PÁÙñ¸p¤F¦V ­»´ä©M¿Dªù¨ÑÀ³1000¸U¾¯ªº¨óij¡C[206]­»´ä¬F©²ªí¥Ü±N ¦b 2021 ¦~²Ä¤@©u«×¦¬¨ì²Ä¤@§å 100¸U¾¯¬Ì­]¡C[207]

BioNTech ©M´_¬P¦P·N ¦b 2021 ¦~¦V¤¤°ê¨ÑÀ³¤@§å 1»õ¾¯¡A¦ý¶·¸gºÊºÞ³¡ªù§å­ã¡C[26] [208]³Ìªìªº¨ÑÀ³±N±q BioNTech ¦b¼w°êªº¥Í²£³]¬I¥æ¥I¡C[26] [208]

2021 ¦~ 1 ¤ë¡A½÷·ç©M BioNTech ´£¥X¦b 2021 ¦~ 3 ¤ë¦Ü 2021 ¦~©³¤§¶¡¥H¨C¾¯10¬ü¤¸ªº§é¦©»ù¬°«D¬w¦U¦aªº½Ã¥Í¤u§@ªÌ´£¨Ñ 5000¸U¾¯ COVID-19 ¬Ì­]¡C[209]§@¬°¦^À³¡A«n«D¤wÀò±o 2,000 ¸U¾¯¬Ì­]¡A¹w­p±N¦b 3 ¤ë¤§«áµo³f¡C[210]

2021 ¦~ 4 ¤ë 23 ¤é¡A¼Ú·ù«Å¥¬»P½÷·ç BioNTech ñ­q²Ä¤T¥÷¦X¦P¡A ¦b¨â¦~¤º¤Àµo¦h¹F 18»õ¾¯¤½¥qªº mRNA ¬Ì­]¡C[211]

2021 ¦~ 5 ¤ë 6 ¤é¡A°ê»Ú¶ø©e·|±q Pfizer-BioNTech ÁʶR¤F¬Ì­]¡A¥HÀ°§U§ÓÄ@ªÌ¡B¤u§@¤H­û©M°ÑÁɹB°Ê­û¦b2021 ¦~ 7 ¤ë©óªF¨ÊÁ|¦æªº2020 ¦~®L©u¶ø¹B·|´Á¶¡¶i¦æ§K¬Ì±µºØ¡C[212] ³ì¡P«ôµnÁ`²Îªº¬F©²©ó 2021 ¦~ 6 ¤ë 9 ¤é©Ó¿Õ¡A¦b¥¼¨Ó¤@¦~¤¤¡A±N¦b¤j¬ù 100 ­Ó°ê®a/¦a°Ï¤Àµo 5 »õ¾¯½÷·ç-BioNTech ¬Ì­]¡C[213]
     
      
ÂÂ 2021-06-15, 09:32 PM #91
¦^À³®É¤Þ¥Î¦¹¤å³¹
GCVincentÂ÷½u¤¤  
IWB
Silent Member
 

¥[¤J¤é´Á: Mar 2017
¤å³¹: 0
¤Þ¥Î:
§@ªÌGCVincent
BNT ¬O4¤ë¶}©lÁ{§É¹êÅç1/2´Á¡A7/27 ©x«Å2/3´Á¡C
11¤ë¤~¶i¤J¤T´Á¡A¶W¹L4¸U¤H°Ñ»P¡C3´ÁÁÙ¨S§¹¥þµ²§ô¡I
12/18½T»{«OÅ@¤O¤§«á¡AFDA ¦P¤é³q¹L EUA
43

Pfizer¤£¬O11¤ë¤~¶i¤J¤T´Á. ©xºô¼g¤F¬O7/27¶}©l²Ä¤T´Á´ú¸Õ

Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints

­ì¤å
"The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,661 participants to date, 41,135 of whom have received a second dose of the vaccine candidate as of November 13, 2020. "

Google½Ķ
"BNT162b2 ªº 3 ´ÁÁ{§É¸ÕÅç©ó 7 ¤ë 27 ¤é¶}©l¡A¨´¤µ¤w©Û¶Ò¤F 43,661 ¦W°Ñ»PªÌ¡AºI¦Ü 2020 ¦~ 11 ¤ë 13 ¤é¡A¨ä¤¤ 41,135 ¤H¤w±µ¨ü²Ä¤G¾¯­Ô¿ï¬Ì­]¡C "
 
ÂÂ 2021-06-15, 09:47 PM #92
¦^À³®É¤Þ¥Î¦¹¤å³¹
IWB²{¦b¦b½u¤W  
cmc0713
Major Member
 

¥[¤J¤é´Á: Aug 2006
¤å³¹: 174
¤Þ¥Î:
§@ªÌ¦Bªº°ÕÅ]¤ý¤j¤H
¬Y¨Ç¤Hªº´¼°Ó¯uªº¬OÄø±oÅý¤H·Q½|¤T¦r¸g.


¨ì©³¬O­þ°¦²´·ú¬Ý¨ì§Ú¦b»¡¡§¤£¥´¬Ì­]¡¨ ?

§Ú¤@ª½¦b»¡ªº, ³£¬O"¯}¬}¦b­þ¸Ì¡I"


§A­Ì³oÀ°¤H,¯uªº³£¬O¦Y½Þ¹}®Æªº!



¬Ý±oÀ´­^¤å¶Ü? ³o¬O¬ì¾Ç´Á¥Z Nature ¤W¥Zªº.

https://i.imgur.com/4D2vFfu.jpg



¨º²É®ÉÄÁ¯uªºÃa±¼¤F¡I ¹L¥h¥L³£¬O°lµÛ¨C­Ó®×¨Ò¦b¶]ªº, ²{¦b®Ú¥»¬O¾ã²Õ©ñ±ó¤F¡I


¥L¯uªº¤£¦æ¤F, ¥L¤@ª½¨S·dÀ´¨ì©³¥Ç¤F¤°»ò¿ù.


§Ú¦A»¡¤@¦¸, ¥xÆW¥ú¾a¥´¬Ì­], µM«á¥´¶}¤@°ï¤pªù¡H
§Ú¥u¯à»¡¨º§A´N¬O­n¦³¤@ª½¥´¬Ì­]ªº¤ß²z·Ç³Æ¡I

¹³¬ì¢Þ»¡ªº, ²{¦b¦n¦n´åÀ»¾Ô°ô¦í©Ò¦³¯}¬}, ¤~¥i¯à¯à¦^¨ì±q«e,
¥~­±¶Ç¬V¨º¬O¥~­±ªº¨Æ,¥L­Ì·R´X­Ó¤ë§â¥þ°ê¤H¥Á½¶}¥´¤@¦¸¬Ì­]¤]¬O¤H®aªº¥»¨Æ.
¦ý§Ú¤£§Æ±æ¥xÆWÅܦ¨¨º¼Ë¡I ¤@ª½­«½Æ¶}¶}ÃöÃö§éÄË·|·dºÆ¤Hªº.




¤HÃþ±o¥H¥Í¦s
¤£¬O¦³¥ú¦³¤ô¦³­¹ª«
¦Ó¬O¦³§Æ±æ

¬Y¤H¾ã¤Ñ­n¬Ì­]
¬F©²ÀqÀq¤£»y
´N¬Oµ¹¤H§Æ±æ

¤£¥Î½|«ü´§©x
«ü´§©x
¨Ã¨S¦³¯u¥¿¦b«ü´§
¥L¥u¬O­ÓÄ묹«~

¸Ü»¡³o­ÓÄ묹«~
¥»¨Ó¥H¬°¥L¦b¥h¦~´N·|³QÄ묹±¼
¨S·Q¨ì¥i¥H¬¡¨ì¤µ¦~
§ó·N¥~ªº
³o­ÓÄ묹«~©~µM¤µ¦~®tÂI³QÄ묹
­ì¥»¥H¬°¤µ¦~¨Æ±¡¥i¥H¸¨¹õ
¨S·Q¨ì........................................................................
ÂÂ 2021-06-16, 12:21 AM #93
¦^À³®É¤Þ¥Î¦¹¤å³¹
cmc0713Â÷½u¤¤  
GCVincent
*°±Åv¤¤*
 

¥[¤J¤é´Á: Nov 2018
¤å³¹: 1,088
¤Þ¥Î:
§@ªÌIWB
Pfizer¤£¬O11¤ë¤~¶i¤J¤T´Á. ©xºô¼g¤F¬O7/27¶}©l²Ä¤T´Á´ú¸Õ

Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints (https://www.pfizer.com/news/press-r...ovid-19-vaccine)

­ì¤å
"The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,661 participants to date, 41,135 of whom have received a second dose of the vaccine candidate as of November 13, 2020. "

Google½Ķ
"BNT162b2 ªº 3 ´ÁÁ{§É¸ÕÅç©ó 7 ¤ë 27 ¤é¶}©l¡A¨´¤µ¤w©Û¶Ò¤F 43,661 ¦W°Ñ»PªÌ¡AºI¦Ü 2020 ¦~ 11 ¤ë 13 ¤é¡A¨ä¤¤ 41,135 ¤H¤w±µ¨ü²Ä¤G¾¯­Ô¿ï¬Ì­]¡C "

¤Þ¥Î:
https://www.pfizer.com/news/press-r...ine-candidate-0
Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study
Goigle ½Ķ
½÷·ç (Pfizer) ©M BioNTech ¿ï¾Ü¤F°w¹ï​​ COVID-19 ªº»â¥ý mRNA ­Ô¿ï¬Ì­]¡A¨Ã¶}©l¤FÃöÁ䪺 2/3 ´Á¥þ²y¬ã¨s


¥h¦~7/27·s»D½Z¬O¼g 2/3´Á¡C
¦Ü©ó¬°¤°»ò¡H¦³¤°»ò¤£¤@¼Ë¡H­n°Ý½÷·ç¡C

¹ê»Ú¦b¬ü°êªºÁ{§É¹êÅç¡A
¥»®×¥¿¦¡¦WºÙ¼g1/ 2 /3´Á¡A
¶}©l©ó2020/4/29¡A
¹w­p¥D­nµ²§ô¤é¡G2021/11/2
¹w­p¬ã¨sµ²§ô¤é¡G2023/5/2
¤T´ÁÀ³¸ÓÁÙ¨Sµ²§ô¡AÁÙ­n¤@¬q®É¶¡¡K¡K

https://clinicaltrials.gov/ct2/show...8¡A#eligibility

¤Þ¥Î:
Study Type  :Interventional  (Clinical Trial)

Estimated Enrollment  :43998 participants

Allocation:Randomized

Intervention Model:Parallel Assignment

Masking:Triple (Participant, Care Provider, Investigator)

Primary Purpose:Prevention

Official Title:A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS

Actual Study Start Date  :April 29, 2020

Estimated Primary Completion Date  :November 2, 2021

Estimated Study Completion Date  :May 2, 2023

¦¹¤å³¹©ó 2021-06-16 12:28 AM ³Q GCVincent ½s¿è.
ÂÂ 2021-06-16, 12:24 AM #94
¦^À³®É¤Þ¥Î¦¹¤å³¹
GCVincentÂ÷½u¤¤  
Puff Daddy
Golden Member
 
Puff Daddyªº¤jÀY·Ó
 

¥[¤J¤é´Á: Mar 2001
±zªº¦í§}: «n¥[¦{ªºªª³õ
¤å³¹: 3,280
¦n¦n¯º...

³ßÅw¸ò§Y±N¶}©ñªº¬ü°ê¤ñ?

¬ü°ê 6/13 ¸¹ªº¼Æ¾Ú¬O ·s¼W½T¶E 12845, ¦º¤` 145, ´«ºâ¦¨¥xÆWªº¤H¤f¬O ·s¼W½T¶E 918 ­Ó ©M ¦º¤` 10.

¬ü°ê³ÌºGªº¼Æ¾Ú¬O¤@¤Ñ·s¼W½T¶E 300,779, ¦º¤` 4406. ´«ºâ¦¨¥xÆWªº¤H¤f¬O¤@¤Ñ·s¼W½T¶E 21,484 ©M ¦º¤` 315.

¬ü°ê²Ö­p½T¶E 3,340 ¸U¤H, ²Ö­p¦º¤` 60 ¸U¤H. ´«ºâ¦¨¥xÆWªº¤H¤f¬O ²Ö­p½T¶E 239 ¸U¤H, ²Ö­p¦º¤` 42,857¤H.

§ÚÁÙ¨SÁ¿¨ì§Ú 14 ­Ó¤ëµLªk¥~­¹, À¹¤f¸n¶W¹L 15 ­Ó¤ë. ¬ù¥b¦~ªº®É¶¡, ¤f¸n, °®¬~¤â, ®ø¬r¼QÃú, ®ø¬rÀã¯È¤y ³£¯Ê³f. ¦³ 3 ­Ó¤ëªº®É¶¡, ¥Õ¦Ì, ªwÄѳ£¯Ê³f.

À\ÆU, ¹s°â¹êÅé°Ó©±, ¦Ê³f¤½¥q¤£ª¾¹D­Ë³¬¤F¦h¤Ö.

§Ú³o¸Ì¬Ì±¡Ãzµo¤F¶W¹L1¦~¤~¦³¬Ì­]¥´, ¬Ì±¡¤~ºâ¬O±±¨î¦í. ¥xÆW¬Ì±¡Ãzµo¤F¦h¤[? 5¤ë¤¤¥H«e¬Ì­]ÁÙ¨S¤H­n¥´, ¶ûªF¶û¦è.

¬ü°ê²{¦bÅwªï¥~°ê¤H¨Ó¥´¬Ì­]. ¥xÆW¥ú¬O¦³¥I°·«O¶Oªº¹´¥Á´N³Q·í§@¬O¹Lµó¦Ñ¹«¤F, ÁÙÅý¨S¦³°·«Oªº¥~°ê¤H¨Ó¥´§K¶Oªº¬Ì­]?

§A¯uªº­n©M¬ü°ê¤ñ?

__________________
I pimp therefore I am

¦¹¤å³¹©ó 2021-06-16 01:40 AM ³Q Puff Daddy ½s¿è.
ÂÂ 2021-06-16, 01:27 AM #95
¦^À³®É¤Þ¥Î¦¹¤å³¹
Puff DaddyÂ÷½u¤¤  
IWB
Silent Member
 

¥[¤J¤é´Á: Mar 2017
¤å³¹: 0
¤Þ¥Î:
§@ªÌGCVincent
¥h¦~7/27·s»D½Z¬O¼g 2/3´Á¡C
¦Ü©ó¬°¤°»ò¡H¦³¤°»ò¤£¤@¼Ë¡H­n°Ý½÷·ç¡C

¹ê»Ú¦b¬ü°êªºÁ{§É¹êÅç¡A
¥»®×¥¿¦¡¦WºÙ¼g1/ 2 /3´Á¡A
¶}©l©ó2020/4/29¡A
¹w­p¥D­nµ²§ô¤é¡G2021/11/2
¹w­p¬ã¨sµ²§ô¤é¡G2023/5/2
¤T´ÁÀ³¸ÓÁÙ¨Sµ²§ô¡AÁÙ­n¤@¬q®É¶¡¡K¡K

https://clinicaltrials.gov/ct2/show...8¡A#eligibility

PfizerÀ³¸Ó¬O§â¤G´Á¸ò¤T´Á¤@°_°µ

phase II/III clinical trial

­ì¤å
"Phase II/III clinical trials may also provide more information about the safety and side effects of the new treatment. Combining phases II and III may allow research questions to be answered more quickly or with fewer patients. Also called phase 2/phase 3 clinical trial."

Google½Ķ
"II/III ´ÁÁ{§É¸ÕÅç¤]¥i¯à´£¨Ñ¦³Ãö·sÀøªkªº¦w¥þ©Ê©M°Æ§@¥Îªº§ó¦h«H®§¡C ±N II ´Á©M III ´Á¬Ûµ²¦X¡A¥i¥H§ó§Ö¦a©Î¥Î§ó¤Öªº±wªÌ¦^µª¬ã¨s°ÝÃD¡C ¤]ºÙ¬° 2 ´Á/3 ´ÁÁ{§É¸ÕÅç"
ÂÂ 2021-06-16, 01:47 AM #96
¦^À³®É¤Þ¥Î¦¹¤å³¹
IWB²{¦b¦b½u¤W  
Puff Daddy
Golden Member
 
Puff Daddyªº¤jÀY·Ó
 

¥[¤J¤é´Á: Mar 2001
±zªº¦í§}: «n¥[¦{ªºªª³õ
¤å³¹: 3,280
__________________
I pimp therefore I am
ÂÂ 2021-06-16, 02:23 AM #97
¦^À³®É¤Þ¥Î¦¹¤å³¹
Puff DaddyÂ÷½u¤¤  
¦Bªº°ÕÅ]¤ý¤j¤H
Senior Member
 
¦Bªº°ÕÅ]¤ý¤j¤Hªº¤jÀY·Ó
 

¥[¤J¤é´Á: Apr 2017
±zªº¦í§}: (¢£-_-)¢£ ~ ùäùä
¤å³¹: 1,288
«Ü¦n, ²ö¼w¯Ç¤£´±»¡¥´¬Ì­]«áªº¶Ç¬V´ú¸Õªºµ²ªG,
¼b¥Í¤½¥q¤j¦ÑÁó¥X¨Ó»¡¦Ñ¹ê¸Ü¤F.






©Ò¥H§Ú¥ý«e´N»¡¤F, ²{¦bªºÀô¹Ò®Ú¥»¬OÃļtªº¤Ñ°ó, ¦Ê¦~¤@¹J¡I¦¬³Î­´µæµo¤j°]´N¾a³oªi¤F.
¹j´X­Ó¤ë´N­n¥´¤@ªi, ¯u¬O¤£µo°]¤]Ãø.


¥´¬Ì­]¬Oµ¹«e½u¾Ô¤hÀ¹¿û²¯»P¬ÞµP, ¦ý¤£¬OÅý¥L­A²ÂÀH«K¼ÉÅS¦b¦MÀI¤§¤U, ¨º·Ó¼Ë­n³QÃzÀYªº.
¥B¥´¬Ì­]¤´¦³´X¸U¤À¤§¤@ªº­·ÀI,¬Y¨Ç¦³¤p°ÝÃDªº¬Ì­]ÁÙ·|µy°ª(¤£¤[«e¥xÆW¦³­ÓÂå¥Í´NGG¤F)
Á`¤§±oÅý±µºØªÌ±jÄ饿½TÆ[©À.




¥t¥~,¥u¯à¬èë³o¨ÇµÛ¦WªºÃÄ, ¤£·|³y¦¨ÄY­«ªº«á¿ò¯g, ¤£µM°ÝÃD¥i¯à·|¹³¹q¼v¸Ìºtªº¨º¼Ë...
¨ºÔ£¹q¼v«Ü¦h¤H¬Ý¹L§a?

__________________
------------------------------------------------------



¦A¦¸±j½Õ, ¥´¬Ì­]¤£¬O¦Y¤FµL¼Ä¬P¬P, ¨º¥u¬O«OÅ@¦Û¤v¤£­«¯g, ÁÙ¬O·|¶Ç¬V¡I
¦pªG ¨ä¥L¤H¥´¤F¬Ì­]«oªù¤á¤j¶}¤Ï¦Ó³Q¬ï³z§â¯f¬r±a¶i¨Ó¤F«¨?
ÃÄ°Ó¦­´N»¡§ÜÅé¥u¯à«OÅ@¤£·|­«¯g¥b¦~,¤§«á­n¦A¸É¥´¡I.
±q¨S«OÃÒ¤£·|·P¬V¡I »¡Ô£±µºØ²v¤C¦¨´N¯à¸sÅé§K¬Ì, ³o³£¬O°ò©ó¥´¬Ì­]«á¤£·|·P¬Vªº¼Ò«¬,
°ÝÃD²{¦bªº¬Ì­]®Ú¥»¤£¬O³o¼Ë¡I

°¸¶ýA«õ ²ö¨¯¯R¤@ÂP
EQ©Ô´µ-A¾|§Z
¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ¢æ
(Youtube¼v¤ù)§¹³J¤F¨S·dÀY¤F ³£¸Ó©Ç¦ò©_¦h¸Ü


(Youtube¼v¤ù) ¬ü°ê¬Ý¯f±b³æ:
ÂÂ 2021-06-16, 04:28 AM #98
¦^À³®É¤Þ¥Î¦¹¤å³¹
¦Bªº°ÕÅ]¤ý¤j¤HÂ÷½u¤¤  
NT-MAN
Amateur Member
 
NT-MANªº¤jÀY·Ó
 

¥[¤J¤é´Á: Oct 2008
¤å³¹: 40
§R................

¦¹¤å³¹©ó 2021-06-16 06:06 AM ³Q NT-MAN ½s¿è.
ÂÂ 2021-06-16, 05:55 AM #99
¦^À³®É¤Þ¥Î¦¹¤å³¹
NT-MANÂ÷½u¤¤  
bbking
Major Member
 

¥[¤J¤é´Á: Feb 2000
¤å³¹: 227
²{¦b³o­Ó¯f¬r´N¬O·|¦s¦b¦a²y¤£·|®ø¥¢¤F
©Ò¥H¨¾°ô¹Ò¥~ªº ÁÙ¬O¤@¼Ë¤£¯à¥X¤J°ê §Ú·Q³o¤£¬O¤j®a­nªº
³Ì²×´N¬O¦Ò¬Ì­]¥´¤@¥´ ¤£­n­«¯g´N¦n¤F
¥t¬Ì­]¤]­n°ê»Ú»{ÃÒªº¤~¯à¥X°ê ¤£µM¥X¥h¤U¾÷³õ¤£¬OÁÙ­n¦A¥´¤@°w
ÂÂ 2021-06-16, 07:06 AM #100
¦^À³®É¤Þ¥Î¦¹¤å³¹
bbkingÂ÷½u¤¤  


    ¦^À³


POPIN
¥DÃD¤u¨ã

µoªí¤å³¹³W«h
±z¤£¥i¥Hµo°_·s¥DÃD
±z¤£¥i¥H¦^À³¥DÃD
±z¤£¥i¥H¤W¶Çªþ¥[ÀÉ®×
±z¤£¥i¥H½s¿è±zªº¤å³¹

vB ¥N½X¥´¶}
[IMG]¥N½X¥´¶}
HTML¥N½XÃö³¬



©Ò¦³ªº®É¶¡§¡¬°GMT +8¡C ²{¦bªº®É¶¡¬O09:46 AM.


vBulletin Version 3.0.1
powered_by_vbulletin 2024¡C